Tevogen (TVGN) Free Cash Flow (2022 - 2026)
Tevogen Bio Holdings' (TVGN) quarterly Free Cash Flow came in at -$2.7 million in Q1 2026, up 17.36% YoY from -$2.3 million in Q1 2025, and down 25.33% on a QoQ basis from -$2.2 million in Q4 2025.
Tevogen (TVGN) Free Cash Flow (2022 - 2026) Analysis & Trends
Tevogen Bio Holdings (TVGN) has 5 years of Free Cash Flow data on file, last reported at -$2.7 million in Q1 2026.
- Quarterly Free Cash Flow rose 17.36% year-over-year to -$2.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$11.8 million (up 10.57% YoY) and the FY2025 annual result came in at -$12.4 million, down 3.29% from the prior year.
- Free Cash Flow declined to -$2.7 million in Q1 2026, from -$2.2 million in the prior quarter.
- In the past five years, Free Cash Flow ranged from a high of -$13861.0 in Q4 2022 to a low of -$3.8 million in Q3 2024.
- A 5-year average of -$2.1 million and a median of -$2.2 million in 2023 frame the typical range for Free Cash Flow.
- Annual changes were most pronounced in 2023 — Free Cash Flow plunged 14159.23% — and 2025, when it advanced 28.43%.
- Tracing TVGN's Free Cash Flow over 5 years: stood at -$13861.0 in 2022, then sank by 14159.23% to -$2.0 million in 2023, then plunged by 54.2% to -$3.0 million in 2024, then gained by 28.43% to -$2.2 million in 2025, then retreated by 25.33% to -$2.7 million in 2026.
- The last three Free Cash Flow figures came in at -$2.7 million (Q1 2026), -$2.2 million (Q4 2025), and -$3.6 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -563.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 437.80 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 292.04 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 433.84 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -95.09 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 477.44 Mn |
| 10 | Tevogen | 25.62 Mn | 25.62 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2.73 Mn |
| Mar 31, 2026 | -2.73 Mn |
| Dec 31, 2025 | -2.18 Mn |
| Dec 31, 2025 | -2.18 Mn |
| Sep 30, 2025 | -3.65 Mn |
| Sep 30, 2025 | -3.65 Mn |
| Jun 30, 2025 | -3.19 Mn |
| Jun 30, 2025 | -3.19 Mn |
| Mar 31, 2025 | -3.31 Mn |
| Mar 31, 2025 | -3.31 Mn |
| Dec 31, 2024 | -3.05 Mn |
| Dec 31, 2024 | -3.05 Mn |
| Sep 30, 2024 | -3.80 Mn |
| Sep 30, 2024 | -3.80 Mn |
| Jun 30, 2024 | -2.98 Mn |
| Jun 30, 2024 | -2.98 Mn |
| Mar 31, 2024 | -2.16 Mn |
| Mar 31, 2024 | -2.16 Mn |
| Dec 31, 2023 | -1.98 Mn |
| Dec 31, 2023 | -1.98 Mn |